The closest thing to a COVID 'cure'? Eli Lilly's combination antibody drug cuts the risk of COVID-19 hospitalization and death by 87%, study finds
The combination treatment, a mixture of two drugs, recognizes the coronavirus and attaches to it, preventing it from spreading throughout the body
Half a group of 769 mild-to-moderate COVID-19 patients at high risk of severe illness were given the drugs and another half given the placebo
There four hospitalizations and zero deaths among the patients given the treatment and 11 hospitalizations and four deaths among the placebo group
Researchers determined the combination therapy reduced the risk of hospitalization and death by 87 percent compared to a placebo
Last month, the U.S. agreed to buy 100,000 doses of the antibody therapy, expected to be delivered by the end of the month, for $210 million
By Mary Kekatos Senior Health Reporter For Dailymail.com
Published: 15:57 EST, 10 March 2021 | Updated: 16:07 EST, 10 March 2021
Eli Lilly & Co says its combination antibody therapy is effective at treating mild to moderate cases of COVID-19.
The treatment, a mixture of drugs bamlanivimab and etesevimab, was developed by Indianapolis-based Lilly and the Canadian company AbCellera.
It recognizes the virus once a person is infected and attaches to it, preventing the pathogen from entering human cells, and therefore neutralizing it.
more
https://www.dailymail.co.uk/health/article-9347813/Eli-Lillys-combination-antibody-therapy-COVID-19-cuts-risk-hospitalization-death-87.html